Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

548P - Phase I study of oral GZ17-6.02 in patients with advanced solid tumors or lymphoma

Date

16 Sep 2021

Session

ePoster Display

Presenters

Alain Mita

Citation

Annals of Oncology (2021) 32 (suppl_5): S583-S620. 10.1016/annonc/annonc699

Authors

A. Mita1, M. Mita2, F. Tsai3, R.P. Moore4, J. Bailes4, M. Matrana5

Author affiliations

  • 1 Oncology, Cedars Sinai, 90048 - Los Angeles/US
  • 2 Oncology, Cedars-Sinai Medical Center, Los Angeles/US
  • 3 Oncology, Honor Health Research and Innovation Institute, Scottsdale/US
  • 4 R&d, Genzada Pharmaceuticals, 67502 - HUTCHINSON/US
  • 5 Oncology, Ochsner Cancer Institute, New Orleans/US
More

Abstract 548P

Background

Botanical molecules, such as curcumin, have been extensively studied as a potential anti-cancer therapeutics. Research has recently identified a combination of three synthetically manufactured natural molecules for clinical study in oncology. An optimized ratio of isovanillin, harmine, and curcumin has shown preclinical evidence of in-vitro and in-vivo activity with evidence of super enhancer modulation providing rationale for clinical study.

Methods

Phase I, multicenter, open-label, dose-escalation, safety, pharmacodynamic and pharmacokinetic study of GZ17-6.02 given orally on a daily x 28 day of schedule in patients with advanced solid tumors or lymphoma. The dose escalation followed a standard 3+3 design. Thirty-six patients have accrued to the study, 24 in the dose escalation phase and 12 in the dose expansion phase at the recommended phase two dose (RP2D) of 375mg bid.

Results

GZ17-6.02 has demonstrated to be generally well tolerated with an acceptable safety profile. Grade 3/4 transaminitis was observed in 6 out of 32 evaluable patients and was the dose limiting toxicity. Transaminitis was readily reversible upon discontinuation, no elevations of bilirubin were observed and 3 of the 6 cases of elevated transaminitis occurred above the RP2D. Grade 3/4 dizziness was observed in one patient. Two patients contracted COVID-19 while on study, though no dose interruptions or modifications were necessary. An investigator assessed partial response was reported in a patient with EGFR mutated Non-Small Cell Lung Cancer. Stable disease was observed in six additional patients at various dose levels within the study. Additional evidence of radiological tumor regression was also observed. Clinical benefit was observed in seven patients as assessed by investigators.

Conclusions

GZ17-6.02 was biologically active and demonstrated an acceptable and manageable safety profile in a heavily pretreated patient population with various malignancies. This phase 1 data provides rational for further investigation in a phase 2 setting to determine GZ17-6.02’s safety and potential efficacy in defined patient populations, both as monotherapy and in combination with other therapeutics.

Clinical trial identification

NCT03775525

Editorial acknowledgement

Legal entity responsible for the study

Genzada Pharmaceuticals USA, Inc.

Funding

Genzada Pharmaceuticals USA, Inc.

Disclosure

R.P. Moore: Financial Interests, Personal and Institutional, Member: Genzada Pharmaceuticals. J. Bailes: Financial Interests, Personal and Institutional, Member: Genzada Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.